MAIC Evidence: Enzalutamide Versus Darolutamide in ARCHES and ARANOTE

Andrew Armstrong, MD, of the Duke Cancer Institute Center for Prostate and Urologic Cancers at Duke University, describes a recent matching-adjusted indirect comparison (MAIC) of enzalutamide versus darolutamide doublet therapy for patients with metastatic hormone-sensitive prostate cancer, which used data from the ARCHES and ARANOTE studies. Dr. Armstrong elaborates on the benefit of enzalutamide with androgen deprivation therapy, and the efficacy of MAIC in comparing trial cohorts.